Suggested remit: To appraise the clinical and cost effectiveness of linzagolix within its marketing authorisation for treating uterine fibroids.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
STA Standard
|
| ID number |
6190
|
Provisional Schedule
| Committee meeting |
04 June 2024 |
Project Team
Email enquiries
Stakeholders
| Companies sponsors |
Theramex (linzagolix) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| |
Welsh Government |
| Patient carer groups |
None |
| Professional groups |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
AstraZeneca (goserelin) (confidentiality agreement signed, participating) |
| |
Ferring Pharmaceuticals (triptorelin) (confidentiality agreement not signed, not partipating) |
| |
Gedeon Richter (relugolix-estradiol-norethisterone acetate) (confidentiality agreement signed, participating) |
| |
Ipsen (triptorelin) (confidentiality agreement not signed, not partipating) |
| |
Takeda UK (leuprorelin) (confidentiality agreement not signed, not partipating) |
| |
Typharm (leuprorelin) (confidentiality agreement not signed, not partipating) |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
None |
|
Date
|
Update
|
|
05 February 2024 - 26 February 2024
|
Draft guidance |
|
09 January 2024
|
Committee meeting |
|
22 November 2023
|
Please note the update to the committee meeting date. The committee meeting is now scheduled to take place on Tuesday 9 January 2024. |
|
04 July 2023
|
Invitation to participate |
|
21 March 2023 - 20 April 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
21 March 2023
|
In progress. Scoping commenced |
|
09 September 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual